By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cellular Dynamics International said today it has closed on a Series B Preferred Stock financing round, raising $30 million.

The financing will be used by the Madison, Wis.-based pluripotent stem cell development firm to launch new iCell induced pluripotent stem cell lines, as well as iCell Endothelial Cells, iCell Neurons, and iCell Hepatocytes for biomedical and pharmaceutical drug development and safety research.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.